Belite Bio Inc (BLTE)

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”...

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”...

Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE)

Belite Bio, Inc. (NASDAQ:BLTE) reported first-quarter results on Wednesday that came in ahead of analyst forecasts, with the clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

Initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA...

Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having...

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio®” or the...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio®” or the...

Form 4 - Statement of changes in beneficial ownership of securities